May 23, 2017 4:33 AM ET

Biotechnology

Company Overview of Enteris BioPharma, Inc.

Company Overview

Unigene Laboratories Inc., Peptelligence(TM) Drug Delivery Platform and Certain Assets comprises Peptelligence™ drug delivery, recombinant manufacturing platforms, and company’s Biotechnologies Strategic Business Unit. Peptelligence offers intellectual property covering drug delivery and manufacturing technologies, peptide research and development, and proprietary know-how.

,  

United States

Key Executives for Enteris BioPharma, Inc.

Executive Chairman and Chief Executive Officer
Age: 60
President and Chief Financial Officer
Age: 52
Chief Operating Officer
Age: 55
Vice President of Business Development
Compensation as of Fiscal Year 2016.

Enteris BioPharma, Inc. Key Developments

Enteris BioPharma, Inc. Presents at The 24th Annual Future Leaders in the Biotech Industry Conference, Apr-07-2017 10:30 AM

Enteris BioPharma, Inc. Presents at The 24th Annual Future Leaders in the Biotech Industry Conference, Apr-07-2017 10:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Joel A. Tune, Executive Chairman and Chief Executive Officer.

Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic

Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring. Under the terms of the agreement, Enteris BioPharma will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.

Enteris BioPharma, Inc. Enters into Agreement with KeyBioscience AG to Develop Orally Delivered Metabolic Peptide

Enteris BioPharma, Inc. announced the initiation of a clinical manufacturing services agreement with KeyBioscience AG, whereby Enteris will leverage its proprietary Peptelligence platform to advance the development of a proprietary metabolic peptide for the treatment of various indications, including diabetes, obesity, and other metabolic disorders. Under the terms of the agreement, Enteris BioPharma will leverage its Peptelligence platform to manufacture and characterize three oral tablet prototypes of KeyBioscience's metabolic peptide, as well as become the exclusive provider of finished product for use in pre-clinical and proof-of-concept clinical trial research.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enteris BioPharma, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.